Literature DB >> 7509960

Characterization of endothelin isoforms in human heart: endothelin-2 demonstrated.

C Plumpton1, R Champeney, M J Ashby, R E Kuc, A P Davenport.   

Abstract

In humans, three endothelin (ET) isoforms are predicted to exist by analysis of genomic DNA. However, evidence for the presence of all three mature ET peptides and their precursors remains unclear. Our aim was to identify the ET isoforms present in human heart, using radioimmunoassay (RIA) and reverse-phase high-performance liquid chromatography (RP-HPLC). Antisera raised against the ET-1[15-21] terminal sequence were specific for mature ETs, showing no cross-reactivity with their precursor pro-ETs. Antisera raised against the pro-ET-1[31-38] terminal sequence was specific for pro-ET-1, showing no cross-reactivity with other ET peptides. In extracts of human cardiac tissues, the concentrations of immunoreactive (IR) mature ET and pro-ET-1 were found to be as follows: left atrium (n = 3): 282.3 +/- 113.0, 21.9 +/- 11.0, respectively; right atrium (n = 5): 308.3 +/- 95.4, 43.1 +/- 12.8, respectively; left ventricle (n = 6): 218.5 +/- 64.6, 47.9 +/- 11.9, respectively; right ventricle (n = 4): 215.1 +/- 79.8, 53.9 +/- 13.0, respectively (fmol/g wet weight, mean +/- SEM, for total IR mature ET and pro-ET-1, respectively). RP-HPLC showed peaks of immunoreactivity that coeluted with authentic ET-1 in all extracts of human left atria and ventricle tested. In addition, peaks were also present corresponding to ET-2, ET-3, and pro-ET-1. These results suggest that in addition to ET-1 and pro-ET-1, ET-2 and ET-3 are present in the human heart.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7509960     DOI: 10.1097/00005344-199322008-00009

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

1.  Differential distribution of endothelin peptides and receptors in human adrenal gland.

Authors:  A P Davenport; S L Hoskins; R E Kuc; C Plumpton
Journal:  Histochem J       Date:  1996-11

Review 2.  Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer.

Authors:  Lowell Ling; Janet J Maguire; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

3.  Generation and characterization of an endothelin-2 iCre mouse.

Authors:  Joseph A Cacioppo; Yongbum Koo; Po-Ching Patrick Lin; Arnon Gal; CheMyong Ko
Journal:  Genesis       Date:  2015-02-12       Impact factor: 2.487

4.  Differential gene expression in mouse retina related to regional differences in vulnerability to hyperoxia.

Authors:  Yuan Zhu; Riccardo Natoli; Krisztina Valter; Jonathan Stone
Journal:  Mol Vis       Date:  2010-04-28       Impact factor: 2.367

5.  Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart.

Authors:  M G Peter; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

6.  Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm.

Authors:  C Plumpton; W G Haynes; D J Webb; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

7.  Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats.

Authors:  S M Gardiner; J E March; P A Kemp; J J Mullins; T Bennett
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

8.  Secretion of endothelin-1 and endothelin-3 by human cultured vascular smooth muscle cells.

Authors:  J C Yu; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

Review 9.  Endothelin.

Authors:  Anthony P Davenport; Kelly A Hyndman; Neeraj Dhaun; Christopher Southan; Donald E Kohan; Jennifer S Pollock; David M Pollock; David J Webb; Janet J Maguire
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.